{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T10:39:38Z","timestamp":1766486378253},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2001,11,1]],"date-time":"2001-11-01T00:00:00Z","timestamp":1004572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2001,11]]},"DOI":"10.1006\/clim.2001.5113","type":"journal-article","created":{"date-parts":[[2002,9,16]],"date-time":"2002-09-16T15:45:11Z","timestamp":1032191111000},"page":"146-151","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of Epidermolysis Bullosa Acquisita with the Humanized Anti-Tac mAb Daclizumab"],"prefix":"10.1006","volume":"101","author":[{"given":"C.A.","family":"Egan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.D.","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.B.","family":"Yancey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1006\/clim.2001.5113_RF1","series-title":"Dermatology in General Medicine","first-page":"702","article-title":"Epidermolysis bullosa acquisita","author":"Woodley","year":"1999"},{"key":"10.1006\/clim.2001.5113_RF2","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archderm.135.8.954","article-title":"Mucosal morbidity in patients with epidermolysis bullosa acquisita","volume":"135","author":"Luke","year":"1999","journal-title":"Arch. Dermatol."},{"key":"10.1006\/clim.2001.5113_RF3","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1056\/NEJM198404193101602","article-title":"Identification of the skin basement-membrane autoantigen in epidermolysis bullosa acquisita","volume":"310","author":"Woodley","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2001.5113_RF4","first-page":"1389","article-title":"Epitope mapping of type VII collagen","volume":"92","author":"Lapiere","year":"1993","journal-title":"J. Clin. Invest."},{"key":"10.1006\/clim.2001.5113_RF5","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0190-9622(84)80459-4","article-title":"Epidermolysis bullosa acquisita-a pemphigoid-like disease","volume":"11","author":"Gammon","year":"1984","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1006\/clim.2001.5113_RF6","doi-asserted-by":"crossref","first-page":"i109","DOI":"10.1136\/ard.59.suppl_1.i109","article-title":"Advances in interleukin 2 receptor targeted treatment","volume":"59","author":"Morris","year":"2000","journal-title":"Ann. Rheum. Dis."},{"key":"10.1006\/clim.2001.5113_RF7","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2165\/00003495-199958060-00006","article-title":"Daclizumab: A review of its use in the prevention of acute rejection in renal transplant recipients","volume":"58","author":"Wiseman","year":"1999","journal-title":"Drugs"},{"key":"10.1006\/clim.2001.5113_RF8","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1073\/pnas.96.13.7462","article-title":"Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I\/II clinical trial","volume":"96","author":"Nussenblatt","year":"1999","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1006\/clim.2001.5113_RF9","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/0190-9622(91)70151-Q","article-title":"Direct immunofluorescence microscopy of 1 mol\/L sodium chloride-treated patient skin","volume":"24","author":"Domloge-Hultsch","year":"1991","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1006\/clim.2001.5113_RF10","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/S0190-9622(96)90604-0","article-title":"Reactivity of autoantibodies from patients with defined subepidermal bullous diseases against 1 mol\/L salt-split skin","volume":"35","author":"Lazarova","year":"1996","journal-title":"J. Am. Acad.Dermatol."},{"key":"10.1006\/clim.2001.5113_RF11","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1126\/science.3095922","article-title":"Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions","volume":"234","author":"Sharon","year":"1986","journal-title":"Science"},{"key":"10.1006\/clim.2001.5113_RF12","doi-asserted-by":"crossref","first-page":"855","DOI":"10.4049\/jimmunol.139.3.855","article-title":"Structure-function relationships for the IL 2-receptor system","volume":"139","author":"Robb","year":"1987","journal-title":"J. Immunol."},{"key":"10.1006\/clim.2001.5113_RF13","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1084\/jem.183.4.1587","article-title":"Metabolism of Tac (IL2Ralpha): Physiology of cell surface shedding and renal catabolism, and suppression of catabolism by antibody binding","volume":"183","author":"Junghans","year":"1996","journal-title":"J. Exp. Med."},{"key":"10.1006\/clim.2001.5113_RF14","first-page":"97","article-title":"Soluble interleukin 2 receptors in patients after bone marrow transplantation","volume":"6","author":"Siegert","year":"1990","journal-title":"Bone Marrow Transplant."},{"key":"10.1006\/clim.2001.5113_RF15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1182\/blood.V95.1.83","article-title":"Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft versus-host disease","volume":"95","author":"Przepiorka","year":"2000","journal-title":"Blood"},{"key":"10.1006\/clim.2001.5113_RF16","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJM199801153380304","article-title":"Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation","volume":"338","author":"Vincenti","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"10.1006\/clim.2001.5113_RF17","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1067\/mjd.2000.106515","article-title":"Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis","volume":"43","author":"Krueger","year":"2000","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1006\/clim.2001.5113_RF18","first-page":"6977","article-title":"IL-2R alpha-directed monoclonal antibodies provide effective therapy in a murine model of adult T-cell leukemia by a mechanism other than blockade of IL-2\/IL-2R alpha interaction","volume":"60","author":"Phillips","year":"2000","journal-title":"Cancer Res."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661601951137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661601951137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T18:20:29Z","timestamp":1680546029000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661601951137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,11]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2001,11]]}},"alternative-id":["S1521661601951137"],"URL":"https:\/\/doi.org\/10.1006\/clim.2001.5113","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2001,11]]}}}